Karine Marinier

Karine Marinier

Auto-generated profile, based on publicly available information

Karine Marinier

Real World Solutions , IQVIA , Courbevoie 92400 , France

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2019 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Open access
PDF file
KMKarine Marinier
Karine Marinier
PMPauline Macouillard
Pauline Macouillard
MCMartine de Champvallins
Martine de Champvallins
NDNicolas DELTOUR
Nicolas DELTOUR
NPNeil Poulter
Neil Poulter
Giuseppe ManciaGiuseppe Mancia
Giuseppe Mancia
Purpose: To compare the effectiveness on blood pressure (BP) of initial two‐drug therapy versus monotherapy in hypertensive patients.Methods: Using the Clinical Practice Research Datalink, linked with Hospital Episode Statistics and Office for National Statistics, we identified a cohort of adults with uncontrolled hypertension, initiating one or two antihypertensive drug classes between 2006 and 2014. New users of two drugs and monotherapy were matched 1:2 by propensity score. Main exposure was “as‐treated,” ie, until first regimen change. Primary and secondary endpoints were systolic and diastolic BP control and major adverse cardiovascular event (MACE), respectively. Hazard ratios (HR) and 95% confidence intervals (CI) were estimated using Cox proportional hazard models.Results: Of 54 523 eligible patients, 3256 (6.0%) were initiated to a two‐drug combination. Of these, 2807 were matched to 5614 monotherapy users. Mean exposure duration was 12.7 months, with 76.5% patients changing their initial regimen. Two‐drug therapy was associated with a clinically significant BP control increase in all hypertensive patients (HR = 1.17 [95%CI: 1.09‐1.26]), more so in patients with grade 2‐3 hypertension (HR = 1.28 [1.17‐1.41]). An increase of 27% in BP control (HR = 1.27 [1.08‐1.49]) was observed in patients initiating an ACEi+CCB combination compared with initiators of either single class. No significant association was found between two‐drug therapy and MACE. Several sensitivity analyses confirmed the main findings.Conclusions: Few patients initiated therapy with two drugs, reflecting UK guidelines' recommendation to start with monotherapy. This study supports the greater effectiveness of two‐drug therapy as the initial regimen for BP control.

9 May 2024 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Open access
Rosa GiniRosa Gini
Rosa Gini
RPRomin Pajouheshnia
Romin Pajouheshnia
HGHelga Gardarsdottir
Helga Gardarsdottir
DBDimitri Bennett
Dimitri Bennett
LLLin Li
Lin Li
GHGillian Hall
Gillian Hall
Purpose: Real‐world evidence (RWE) is increasingly used for medical regulatory decisions, yet concerns persist regarding its reproducibility and hence validity. This study addresses reproducibility challenges associated with diversity across real‐world data sources (RWDS) repurposed for secondary use in pharmacoepidemiologic studies. Our aims were to identify, describe and characterize practices, recommendations and tools for collecting and reporting diversity across RWDSs, and explore how leveraging diversity could improve the quality of evidence.Methods: In a preliminary phase, keywords for a literature search and selection tool were designed using a set of documents considered to be key by the coauthors. Next, a systematic search was conducted up to December 2021. The resulting documents were screened based on titles and abstracts, then based on full texts using the selection tool. Selected documents were reviewed to extract information on topics related to collecting and reporting RWDS diversity. A content analysis of the topics identified explicit and latent themes.Results: Across the 91 selected documents, 12 topics were identified: 9 dimensions used to describe RWDS (organization accessing the data source, data originator, prompt, inclusion of population, content, data dictionary, time span, healthcare system and culture, and data quality), tools to summarize such dimensions, challenges, and opportunities arising from diversity. Thirty‐six themes were identified within the dimensions. Opportunities arising from data diversity included multiple imputation and standardization.Conclusions: The dimensions identified across a large number of publications lay the foundation for formal guidance on reporting diversity of data sources to facilitate interpretation and enhance replicability and validity of RWE.

6 November 2019 in Osteoporosis International
Verified
Journal Article
Closed access
PDF file
KBK. Berencsi
K. Berencsi
ASA. Sami
A. Sami
MAM.S. Ali
M.S. Ali
KMK. Marinier
K. Marinier
NDN. Deltour
N. Deltour
DPD. Prieto-Alhambra
D. Prieto-Alhambra

12 November 2024 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Open access
SCSandrine Colas
Sandrine Colas
TNTiffany Nishikawa
Tiffany Nishikawa
IDIsabelle Dresco
Isabelle Dresco
SKSigal Kaplan
Sigal Kaplan
KMKarine Marinier
Karine Marinier
MTMassoud Toussi
Massoud Toussi
Purpose: To assess the impact of the 2018 European additional risk minimisation measures (aRMMs) regarding the use of valproate in women of childbearing potential (WCBP) and during pregnancy.Methods: A cross‐sectional, non‐interventional survey conducted in six European countries among 1982 healthcare professionals (HCPs) (July–October 2020) and 779 WCBP treated with valproate for epilepsy, bipolar disorder or other indications (August 2020–February 2021). HCPs were prescribing physicians (neurologists, psychiatrists, paediatricians and GPs), gynaecologists and pharmacists. Prespecified criteria were defined for success in the dimensions of awareness, knowledge and behaviour (correct answers to ≥ 80% of questions at individual level) and overall success (≥ 90%/80% successful HCPs/patients respectively, in the behaviour dimension and one of the two other dimensions).Results: HCPs and patients did not meet the success criteria either overall or in any dimension. Highest success rates were in the behaviour dimension for gynaecologists (71.7%), pharmacists (49.7%) and patients (51.2%), and in the awareness dimension for prescribing physicians (23.6%). HCPs reported being unfamiliar with some educational materials and lacked knowledge of detailed prescribing conditions for valproate and the need for contraception regardless of sexual activity. More than 50% of patients were aware of the relevant patient materials and knew about the teratogenic risks of valproate.Conclusion: Self‐reported levels of awareness, knowledge and behaviour varied considerably by HCP type and among patient respondents. Further investigation is needed into why certain measures of the pregnancy prevention programme are not well known and followed, to improve their effectiveness. This will be addressed in a qualitative study which will be based on interviews with HCPs and patients.

6 May 2026 in Archives of Cardiovascular Diseases
Verified
Journal Article
Closed access
RIRichard Isnard
Richard Isnard
FRFrançois Roubille
François Roubille
MDMaxime Doublet
Maxime Doublet
MKMehdi Kadri
Mehdi Kadri
KMKarine Marinier
Karine Marinier
DLDamien Logeart
Damien Logeart

1 January 2026 in Health & Social Care in the Community
Verified
Journal Article
Open access
PDF file
SCSandrine Colas
Sandrine Colas
TNTiffany Nishikawa
Tiffany Nishikawa
DBDavid Bigat
David Bigat
JSJohn Solomon
John Solomon
SKSigal Kaplan
Sigal Kaplan
MKMarie-Laure Kürzinger
Marie-Laure Kürzinger
Purpose: To report UK‐specific results from a post‐authorisation safety study (PASS) that assessed the impact of additional risk minimisation measures (aRMMs), issued in Europe in 2018, regarding the use of valproate in women of childbearing potential (WCBP) and during pregnancy. Methods: The PASS was conducted among three healthcare professional (HCP) target groups (prescribing physicians, gynaecologists and pharmacists) and among WCBP treated with valproate for epilepsy, bipolar disorder or other indications. In the United Kingdom, 374 HCPs and 194 patients participated. Criteria for success were prespecified in the dimensions of awareness, knowledge and behaviour (expected answers given to ≥ 80% of questions) and overall success (≥ 90% of HCPs or ≥ 80% of patients giving expected answers in the behaviour dimension plus one of the two other dimensions). Results: Reported scores for HCPs and patients did not meet the prespecified individual dimension or overall success criteria. However, they were implementing many of the requirements of the aRMMs. Among dimensions, HCPs recorded highest scores for awareness (44%–76%). For behaviour, prescribing physicians scored highly for ensuring patients’ understanding of the annual review form (88%–97%), advising patients of the need for contraception (89%–99%) and counselling patients planning for pregnancy (67%–100%). Reported patient scores were highest in the behaviour dimension (66%), particularly for using contraception (90%) and intending to consult their physician if pregnant (95%) or planning to become pregnant (90%). Conclusion: Although prespecified criteria for success were not met, reported scores indicate that many of the requirements were being implemented to ensure appropriate use of valproate in WCBP. However, further investigation is needed into the barriers preventing adherence with certain measures of the pregnancy prevention programme.